Cargando…

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma

Immune checkpoint blockade (ICB) expands the therapeutic options for metastatic lung cancer nowadays representing a standard frontline strategy as monotherapy or combination therapy, as well as an option in oncogene-addicted NSCLC after exhaustion of targeted therapies. Predictive markers are urgent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Budczies, Jan, Kirchner, Martina, Kluck, Klaus, Kazdal, Daniel, Glade, Julia, Allgäuer, Michael, Kriegsmann, Mark, Heußel, Claus-Peter, Herth, Felix J., Winter, Hauke, Meister, Michael, Muley, Thomas, Fröhling, Stefan, Peters, Solange, Seliger, Barbara, Schirmacher, Peter, Thomas, Michael, Christopoulos, Petros, Stenzinger, Albrecht
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808386/ https://www.ncbi.nlm.nih.gov/pubmed/33520406 http://dx.doi.org/10.1080/2162402X.2020.1860586

Ejemplares similares

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma
por: Kazdal, Daniel, et al.
Publicado: (2021)

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
por: Budczies, Jan, et al.
Publicado: (2022)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
por: Romanovsky, Eva, et al.
Publicado: (2023)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
por: Blasi, Miriam, et al.
Publicado: (2022)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples
por: Kriegsmann, Katharina, et al.
Publicado: (2021)

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
por: Neumann, Olaf, et al.
Publicado: (2022)

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
por: Kirchner, Martina, et al.
Publicado: (2019)

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
por: Rempel, E., et al.
Publicado: (2022)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
por: Eichhorn, Florian, et al.
Publicado: (2021)

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer
por: Kazdal, Daniel, et al.
Publicado: (2017)

Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition
por: Baum, Philip, et al.
Publicado: (2021)

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer
por: El Shafie, R.A., et al.
Publicado: (2021)

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib
por: Kunz, Julia, et al.
Publicado: (2022)

Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie
por: Kahles, Andy, et al.
Publicado: (2023)

AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients
por: Schneider, Marc A., et al.
Publicado: (2017)

Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer
por: Kriegsmann, Mark, et al.
Publicado: (2018)

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients
por: Menzel, Michael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q9bhrg42tkr8ksvfmkmnn5bvso